This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LSX Europe
Life Science Fundraising & Investment
7-8 April 2027 - Main days, Lyon, France6 April 2027 - Pre-day forums (Life Science Companies only)
Menu
keyboard_arrow_right

Day Two - Western European Summer Time (WEST)

keyboard_arrow_leftSearch & Filter
search
Day Two - Western European Summer Time (WEST)
search
Showing 1 of 1 Streams
09:00 - 09:05
LSX Welcome Address: Biotech Leaders
  • Adam Griffiths - Portfolio Manager, LSX
09:05 - 09:35
State of Biotech Markets: A Forward-looking View
  • Cody Powers - Partner, ZS Associates
09:35 - 10:30
Investment, Innovation, and Influence: Reimagining Europe’s Role in Global Life Sciences
  • Adam Schoen - Partner, Brown Rudnick
  • Zina Affas Besse - Partner and Deputy Head of Healthcare Private Equity, BNP Paribas Asset Management
  • Giovanni Mariggi - Partner, Medicxi
  • Holger Kissel - SVP Scientific Relations & Liaison, BioNtech
  • Mary Clark - CEO, Optimum Strategic Communications
Showing 3 of 3 Streams
11:30 - 12:10
Global Hotbeds of Innovation: Where Will the Next Breakthroughs Come From?
  • Sascha Berger - Investment Director, NEOM
  • Ester Sklarsky - Principal, Sound Bioventures
  • Luka Nicin - VC Investor, Pace Ventures
  • Marc Dechamps - CEO, Bioxodes
  • Artemy Shumskiy - Senior Associate, LongeVC
  • Neill Moray Mackenzie - Partner and Entrepreneur in Residence, ArgoBio Studio
12:10 - 12:50
From Lab to Launch: How to Turn Academic Research into a Viable Biotech
  • Deborah Sterling - Director, Sterne Kessler
  • Martin Svorc - Director, Neurology & Immunology, Fertility Business Development, Merck KGaA
  • Laura Ferguson - Director, Platform Technologies Search and Evaluation, AstraZeneca
  • Danuta Gawel - Chief Research and Development Officer, Mavatar
  • Stephanie Marrus - Founder, Redwood Innovation Advisors
11:10 - 11:30
Partnering with Debiopharm
  • Damian Ibanez - Associate Search & Evaluation Oncology, Debiopharm
11:30 - 12:10
The Current State of Biotech Investing: Where is the Smart Money Going in 2026?
  • Hakan Goker - Managing Director, M Ventures
  • Jamie Bignal - Director, HSBC Innovation Banking
  • João Incio - General Partner, Biovance Capital
  • Achim Plum - Managing Director, HTGF
  • Joao Ribas - Venture Partner, Novo Holdings
12:10 - 12:50
Biotech’s Rising South: Mapping Investment and Innovation in Southern Europe
  • João Eurico Cabral da Fonseca - Dean, Lisbon School of Medicine, University of Lisbon
  • Ricardo Henriques - Managing Partner & Co-founder, Biovance Capital
  • Natalia Misciattelli - CEO, AAVantgarde Bio
  • Antonio Herce - Director - Life Sciences, Inveready
  • Emilio Erazo-Fischer - Operating Partner, Asabys Partners
11:10 - 11:30
Future-proofing Your Launch: Data and Strategies for What’s Next

The healthcare industry has always evolved, but the scale and pace of change have accelerated in recent years—with major shifts across policy, technology and the broader healthcare landscape. What do these changes mean for biopharma companies and how they bring products to market? How do they affect revenue potential, clinical program design and other critical launch preparations?


Join this session to:

  • Hear the latest research and data on what drives launch success today
  • Gain practical insights on how to prepare for future market dynamics
  • Learn from an expert panel discussion exploring real-world examples and implications for launch strategy
  • Mark Rayward-Smith - Principal, ZS
11:30 - 12:10
Future-proofing Your Launch: Data and Strategies for What’s Next Panel Discussion
  • Mark Rayward-Smith - Principal, ZS
  • Sandra von Meier - Head of Business Development Life Science, Terra Quantum
  • Pawel Przewiezlikowski - CEO, Ryvu Therapeutics
  • Georg Pirmin Meyer - SVP & Head of International, Blueprint Medicines
12:10 - 12:50
Early Commercial Strategy: Building Value from Day One
  • Eric Falcand - Chairman, Lytix Biopharma
  • Rasmus Just - Global Head, Business Development, M&A, Licensing, Search & Evaluation, ALK
  • Elin Trampe - CEO, Dicot Pharma
  • Jonas Båtelson - CEO, Curacell
  • Khatereh Ahmadi - Venture Partner, XGEN Venture
  • Matthias Hess - Former SVP Head of Europe, SpringWorks Therapeutics
Showing 3 of 3 Streams
14:00 - 14:50
Rare Diseases vs. Broad Indications: Where to Focus Early-Stage Innovation
  • Lori Badura - Head of Global Partnering Rare Disease & Neuroscience, IPSEN
  • Sten Sörensen - CEO, Cereno Scientific
  • Linda McGoldrick - International Independent Director and Board Chair, Alvotech and Member of Council, Ministry for Science and Innovation, Portugal
  • Gražina Mykolaitytė-Nielsen - CEO and Co-Founder, VUGENE
14:50 - 15:40
Next-Gen Modalities: Beyond Antibodies and Small Molecules
  • Christopher Church - Head of Technology Search & Evaluation, Biopharmaceuticals R&D, AstraZeneca
  • Hiro Usuda - Scouting & Transaction Lead, Astellas
  • Jonas Båtelson - CEO, Curacell
  • Cristiana Pires - CEO, Asgard Tx
  • Mike Ward - Global Head of Life Sciences & Healthcare Thought Leadrership, Clarivate
14:00 - 14:50
Navigating Biotech Financing: Balancing Private Resilience and Public Opportunities
  • Søren Lemonius - Managing General Partner, Sunstone Life Science Ventures
  • Fabian Scheugenpflug - Principal, Plug and Play
  • Pierre Joffrin - Senior Associate, Syncona
  • Daniel Forman - Partner, Lowenstein Sandler
  • Hans T. Schambye - CEO, BOOST Pharma
14:50 - 15:40
Inside the Investor Mind: How Biotech VCs Are Making Decisions Today
  • Tim Lohoff - Principal, Forbion
  • Max Klement - Partner, Venture Investments, Novo Holdings
  • Nuno Alves - Associate Director, Business Development, Astellas
  • Georgina Askeland - Principal, Hadean Ventures
  • Phil Masterson - Associate Director, Ventures, Cancer Research Horizons
  • Chris Maggos - Managing Director, Cohesion Bureau
14:00 - 14:50
Oncology’s Next Frontier: Future Opportunities in an Ever-Growing Market
  • Sonal Patel - VP, Oncology Scientific Innovation, Johnson & Johnson Innovation
  • Alan Rigby - CEO, Epitopea
  • Ana Slipicevic - CEO, One-Carbon Therapeutics
  • Carlos Buesa - CEO, Oryzon Genomics
  • David Solomon - CEO, Thalia Therapeutics
14:50 - 15:40
How Market Access Strategy Impacts Investment Potential
  • Sukaina Virji - Director, Camarco
  • Sonia Hallen - Investment Manager, Gilde Healthcare
  • Ian O'Connell - CFO, Poolbeg Pharma
Showing 1 of 1 Streams
16:20 - 17:00
Biotech’s Next Frontier: Unlocking the Future of Early-Stage Funding
  • Roel Bulthuis - Managing Partner, Head of Investments, Syncona
  • Arno de Wilde - Managing Director, EQT Life Sciences
  • Josh Little - Senior Associate, M&A, A&O Shearman
  • Tobias Horneman-Thielcke - Partner, Eir Ventures
  • Hans T. Schambye - CEO, BOOST Pharma
  • Megan McMellon - Senior Associate, Commercial IP, A&O Shearman
17:00 - 17:40
Strategic Pharma Business Development: M&A and Beyond
  • Melanie Howard - Partner, Latham & Watkins
  • Chloé Leprêtre - Head of Global R&D Search & Evaluation, Servier
  • Stefano Cottignoli - SVP, Head of Global Business & Corporate Development, Chiesi Group
  • Daniel Abernathy - Director, McQuade Center for Strategic Research & Development, Otsuka
  • Caroline Austin - VP, Head of Transactions, Business Development, AstraZeneca
Day One - Pre-Day
NextDay Two Showcases
Filter
Streams
Clear
Formats
Choose Day